• Users Online: 110
  • Print this page
  • Email this page
Year : 2022  |  Volume : 1  |  Issue : 1  |  Page : 7-13

Bacille Calmette – Guérin vaccination: Experience from the past and its perspective further

Department of Research, Parabolic Biologicals, 1320 Beauvechain, Belgium

Correspondence Address:
Roland Maes
Parabolic Biologicals, Rue de l' Ecluse, 2, 1320 Beauvechain
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jpdtsm.jpdtsm_1_21

Rights and Permissions

Today, tuberculosis (TB) kills one person in 14 s in India and one in 12 s, worldwide (that comes to approximate 4000 people per day). The majority of cases are invisible because they are either confined in sanatoria and/or do not encumber regular hospitalization, in contrast to SARS-CoV-2 (COVID-19) pandemic. The COVID-19 pandemy has put in glaring light the fragility of the elders, the minorities, and the exposure of the healthcare agents that was similar to Mycobacterium tuberculosis infection. The mayhem of coronavirus might be repeated itself with the foreseen rise of TB, that would affect the healthcare system resemble much of what occurred during the last 3 years (2019-till date). We must keep in mind that currently TB is neglected and that it might expand again, due to the COVID-19 pandemic. In this review, the past and further perspective of Bacille Calmette–Guérin (BCG) vaccination is described. In addition, the tuberculin skin-testing which has a complex and long story was reviewed. Furthermore, the effect and side-effect of BCG vaccination compared and discussed.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded73    
    Comments [Add]    

Recommend this journal